Please login to the form below

Not currently logged in


This page shows the latest mis-marketing news and features for those working in and with pharma, biotech and healthcare.

Double win for J&J's schizophrenia franchise

Double win for J&J's schizophrenia franchise

Johnson &Johnson (J&J) will not have to pay a $1.2bn penalty for alleged mis-selling of its schizophrenia drug Risperdal in the US, according to a court ruling. ... Two years ago, a $1.2bn fine was levied on J&J and its Janssen Pharma unit after a jury

Latest news

  • Takeda CEO admits to Blopress mis-marketing Takeda CEO admits to Blopress mis-marketing

    The mis-marketing stemmed from a trial initially reported at a medical conference in 2006 and subsequently published in the journal Hypertension two years later, according to Hasegawa. ... The incident comes amid increased scrutiny of pharma marketing

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....